Scienture Holdings, Inc. (SCNX) · Oct 7, 2026 · Rights change
1-for-25 reverse split — 41.1M shares reduced to approximately 1.64M; effective October 5
Scienture’s reverse split is now effective, cutting shares 25-for-1 to address Nasdaq’s bid-price requirement—but it does not change the underlying pharma business.
Scienture is a specialty-pharma platform moving from product development toward commercialization, with marketed products and an early-development pipeline rather than a mature, broad commercial franchise. This filing does not advance that product story; it primarily repairs the company’s exchange-listing position and resets its share count.
The filing confirms a previously announced capital-structure action, not a new operating milestone. The 1-for-25 reverse split became effective at 12:01 a.m. Eastern Time on October 5, 2026, after stockholders had already authorized the board to choose a ratio between 1-for-2 and 1-for-50. 〔0〕 Because the action and timing were announced on September 30, the effective-date filing is largely confirmation rather than a surprise.
| Measure | Before split | After split |
|---|---|---|
| Common shares outstanding | 41,064,146 | Approximately 1,642,565 |
| Reverse-split ratio | — | 1-for-25 |
| Nasdaq minimum bid-price requirement | — | $1.00 per share |
The immediate business benefit is preserving Nasdaq eligibility, not creating value. The company says the split was intended to regain compliance with Nasdaq’s $1.00 minimum bid-price rule. That removes a near-term listing obstacle, but it does not improve revenue, product approvals, cash generation, or the prospects of the pharmaceutical pipeline.
The split also keeps future financing flexibility intact, with the usual dilution risk still present. The company explicitly says the action is intended to make additional common shares available for future issuance, while options, warrants, and other convertibles were adjusted proportionally rather than economically eliminated. 〔1〕 The reverse split itself does not dilute holders, but the stated financing objective leaves future issuance as an important part of the company’s capital strategy.
Bottom line: This is a necessary listing and capitalization cleanup, not progress in Scienture’s underlying pharmaceutical business. It matters for keeping the company’s market access and financing options open, but the filing adds little new information beyond confirming an already disclosed action.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!